Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Core Insights - Nanobiotix, a late-stage clinical biotechnology company, is focused on pioneering nanoparticle-based approaches to enhance treatment options for cancer and other significant diseases [1][2]. Company Overview - Nanobiotix was incorporated in 2003 and is headquartered in Paris, France. The company has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market since December 2020. It also has subsidiaries in Cambridge, Massachusetts [3]. - The company holds over 25 umbrella patents related to three nanotechnology platforms, which have applications in oncology, bioavailability and biodistribution, and central nervous system disorders [4]. Upcoming Events - Company management will participate in fireside chats at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 5:00 pm EDT in New York, NY. Bart van Rhijn, Chief Financial & Business Officer, will be presenting [1]. - The event will be webcast live, and a replay will be available afterward [1].